La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. We publish proprietary reports and prepare custom reports.
MUC16: old target revisited with new technologies – a pipeline review STUTTGART, Germany I November 10, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active therapy candidates in research and development targeting mucin 16 (MUC16): Pipeline of MUC16-Targeted Immunotherapy. This competitive...
CDH6: clinical PoC of lead anti-CDH6 ADC boosts pipeline – a pipeline review STUTTGART, Germany I November 08, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active therapy candidates in research and development targeting cadherin-6 (CDH6): Pipeline of CDH6-Targeted Immunotherapeutics. This...
MUC1: an old target accessed with new technologies leading to first signs of clinical activity – a pipeline review STUTTGART, Germany I November 06, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active therapy candidates in research and development targeting mucin...
Claudin 18.2: a clinically validated target and plenty of improvement options with new drug modalities – a pipeline review STUTTGART, Germany I September 25, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active therapy candidates in research and development targeting claudin...
PD-L1 and 4-1BB (CD137): promising immuno-oncology therapy combination to overcome on-target-off-tumor toxicity – a pipeline review STUTTGART, Germany I September 24, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active therapy candidates in research and development targeting CD47 or SIRPα: Pipeline...
CD47 and SIRPα: next generation inhibitors to show clinical benefit – a pipeline review STUTTGART, Germany I September 23, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active therapy candidates in research and development targeting CD47 or SIRPα: Pipeline of CD47...
Complement C5: a commercially successful and clinically effective treatment of C5 mediated diseases – a pipeline review STUTTGART, Germany I September 22, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active therapy candidates in research and development targeting the complement C5...
IL-6 and IL-6R: hot targets for underexploited indications – a pipeline review STUTTGART, Germany I September 09, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active IL-6R antagonists and IL-6 inhibitors in R&D: Pipeline of Interleukin-6 (IL-6) Receptor Antagonists and IL6-...
CD40 and CD40L: a versatile target as co-stimulator in cancer and for antagonism in autoimmune diseases – a pipeline review STUTTGART, Germany I September 09, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active CD40 agonists and CD40/L antagonists in R&D:...
CD73: a novel checkpoint protein STUTTGART, Germany I September 08, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active CD73 inhibitors in R&D: Pipeline of CD73 Inhibitors. This competitive intelligence report about CD73 Inhibitors provides an up-to-date competitor evaluation in the...
